Ulteriori informazioni
Informationen zum Autor Robert M. Jones is currently Senior Director of Medicinal Chemistry at Arena Pharmaceuticals and also serve as Adjunct Faculty to the University of Mississippi, Department of Medicinal Chemistry. He has been an active medicinal chemistry researcher for the past 16 years, 13 of which have been in industry. Over the past 8 years his research has focused on metabolic diseases in particular Type 2 Diabetes. His work has led to several compounds entering or being nominated for clinical development, including a first in class GPR119 agonist for T2D. He has also been cited as an inventor of ~ 63 patents / provisional filings; and has published ~ 60 manuscripts and abstracts in the field of medicinal chemistry. Klappentext The incidence of Type 2 diabetes (T2D) has reached epidemic proportions with the World Health Organization (WHO) reporting a global prevalence of 346 million people with T2D accounting for approximately 90% of all cases. Long-term complications include atherosclerosis, heart disease, stroke, end-stage renal disease, retinopathy leading to blindness, nerve damage, sexual dysfunction, frequent infections, and difficult-to-treat foot ulcers, sometimes resulting in lower limb amputation. Individuals suffering from T2D are twice as likely to develop cardiovascular disease or have a stroke, 2 to 6 times more likely to have transient ischemic attacks, and 15 to 40 times more likely to require lower-limb amputation compared with the general population. The cost of undiagnosed diabetes, pre-diabetes, and gestational diabetes brought the total cost of T2D in the United States in 2007 to $218 billion. With such an economic burden, coupled with the fact that many current approved therapies fall short in providing adequate therapeutic advantage in curbing hyperglycemia, the pharmaceutical industry has been heavily focused on discovering novel cellular mechanisms that will address this unmet need. New Therapeutic Strategies for Type 2 Diabetes: Small Molecule Approaches provides the reader with a set of comprehensive accounts of some of the most innovative recent small molecule research strategies targeting T2D. Each chapter has been written by a recognized thought leader in the field. The book concisely explains the biological mechanisms underlying each medicinal chemistry strategy together with up-to-date clinical findings, creating a key go-to text for both biologists and medicinal chemists. Zusammenfassung This book is a state-of-the art review of new therapeutic strategies towards treatments for T2D. Inhaltsverzeichnis Preface, Type 2 Diabetes - Disease Overview; Marketed Small Molecule Dipeptidyl Peptidase IV (DPP4) Inhibitors as a New Class of Oral Anti-diabetics; SGLT2 Inhibitors in Development; Glucokinase Activators in Development; 11 -Hydroxysteroid dehydrogenase type 1 (11 -HSD1) inhibitors in development; Recent Advances in PTP1B Inhibitor Development for the Treatment of Type-2 Diabetes and Obesity; Recent advances in the discovery of GPR119 agonists; Acyl-CoA:diacylglycerol acyltransferase-1 inhibition as an approach to the treatment of type 2 diabetes; Stearoyl-CoA Desaturase 1 (SCD1) Inhibitors: Bench to Bedside Must Only Go through Liver; TGR5 Agonists in Development; The discovery and development of MB07803, a second generation fructose-1,6-bisphosphatase inhibitor with improved pharmacokinetic properties, as a potential treatment of type 2 diabetes; Inhibition of Glycogen Phosphorylase as a Strategy for the Treatment of Type 2 Diabetes; SIRT1 Activators in Development; Long-Chain Free Fatty Acid Receptor Agonists; Glucagon Receptor Antagonists in Development; ACC Inhibitors in Development; Index...
